There are currently 930 clinical trials in Salt Lake City, Utah looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Utah, Huntsman Cancer Institute/University of Utah, Huntsman Cancer Institute and LDS Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Prospective Analysis of Long-Term Clinical Outcomes and 3D Spine Growth in Anterior Vertebral Body Tethering
NCT04914507
Recruiting
Anterior vertebral body tethering (AVBT) is a novel, minimally invasive, growth modulation technique that was recently approved by the FDA under a Humanitarian Device Exemption (HDE). The goal of AVBT is to control curve progression by applying compression on the convex side of the spine deformity. While there has been great initial enthusiasm about the technique as an alternate treatment option to spinal fusion for skeletally immature children with scoliosis, there is a need to better understan... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
11/14/2023
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Scoliosis Idiopathic
Register for Updates
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745
Recruiting
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
Register for Updates
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
NCT06126042
Recruiting
This is a randomised, double-blind, single dose, parallel groups study to compare the PK, immunogenicity, and safety of 3 abatacept products (DRL_AB, RP and RMP) in male NHV.
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
11/08/2023
Locations: ICON, Salt Lake City, Utah
Conditions: Rheumatoid Arthritis
Register for Updates
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Register for Updates
Smart Ankle-Foot Orthosis to Improve Stroke Outcomes: Smart AFO
NCT05619484
Recruiting
The Smart Ankle-Foot Orthosis (Smart AFO) system is an investigational system that combines a diagnostic ankle-foot orthosis with a mobile application to assist clinicians in optimizing an AFO user's gait by adjusting AFO stiffness and range of motion settings, and quantifying functional walking improvements in post-stroke individuals. The purpose of the clinical testing is to evaluate the Smart AFO system with its target users: post-stroke AFO users and orthotists. This may include, but is not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Stroke
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
NCT04956744
Recruiting
This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/26/2023
Locations: Rocky Mountain MS Clinic, Salt Lake City, Utah
Conditions: Multiple Sclerosis
Register for Updates
Improving Myoelectric Prosthetic and Orthotic Limb Control
NCT05509101
Recruiting
The purpose of this study is to improve control of myoelectrically-controlled advanced orthotic devices (an exoskeleton device that use the body's muscle signals to drive movements of a robotic brace) by using advanced predictive decode algorithms, and the use of high count (\> 8) surface electromyographic (sEMG) electrodes.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/21/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Hemiparesis
Register for Updates
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04786574
Recruiting
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 28 days and 12 weeks
Trial Updated:
09/14/2023
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Register for Updates
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT05002270
Recruiting
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Advanced Solid Tumor, NSCLC, CRC
Register for Updates
Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.
NCT06030297
Recruiting
The R61 will perform a four-part double-blind randomized crossover study transitioning from a pretreatment baseline phase, to randomized treatment with either lidocaine or an identical placebo patch, washout, and alternate arm. DLss measures will be obtained before and after each phase. Twice daily report of pain using a visual analogue scale will track severity of ongoing spontaneous pain in participants. The hybrid biomarker will distinguish between placebo and active treatment arms, will sign... Read More
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
09/05/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Peripheral Neuropathy
Register for Updates
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
NCT05181137
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Ulcerative Colitis
Register for Updates
Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)
NCT01196182
Recruiting
Congenital heart defects (CHD) are the most common major human birth malformation, affecting \~8 per 1,000 live births. CHD are associated with significant morbidity and mortality, and are second only to infectious diseases in contributing to the infant mortality rate. Current understanding of the etiology of pediatric cardiovascular disorders is limited. The Congenital Heart Disease GEnetic NEtwork Study (CHD GENES) is a multi-center, prospective observational cohort study. Participants will b... Read More
Gender:
ALL
Ages:
99 years and below
Trial Updated:
08/29/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Congenital Heart Defects
Register for Updates